ME03404B - Derivati policikličnih amida kao cdk9 inhibitori - Google Patents

Derivati policikličnih amida kao cdk9 inhibitori

Info

Publication number
ME03404B
ME03404B MEP-2019-138A MEP2019138A ME03404B ME 03404 B ME03404 B ME 03404B ME P2019138 A MEP2019138 A ME P2019138A ME 03404 B ME03404 B ME 03404B
Authority
ME
Montenegro
Prior art keywords
amide derivatives
cdk9 inhibitors
polycyclic amide
polycyclic
cdk9
Prior art date
Application number
MEP-2019-138A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Kurt Gordon Pike
Bernard Christophe Barlaam
Janet Hawkins
Savi Christopher De
Melissa Marie Vasbinder
Alexander Hird
Michelle Lamb
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME03404B publication Critical patent/ME03404B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Detergent Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2019-138A 2015-06-29 2016-06-27 Derivati policikličnih amida kao cdk9 inhibitori ME03404B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185852P 2015-06-29 2015-06-29
EP16733459.8A EP3313838B1 (en) 2015-06-29 2016-06-27 Polycyclic amide derivatives as cdk9 inhibitors
PCT/EP2016/064899 WO2017001354A1 (en) 2015-06-29 2016-06-27 Polycyclic amide derivatives as cdk9 inhibitors

Publications (1)

Publication Number Publication Date
ME03404B true ME03404B (me) 2020-01-20

Family

ID=56292699

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-138A ME03404B (me) 2015-06-29 2016-06-27 Derivati policikličnih amida kao cdk9 inhibitori

Country Status (38)

Country Link
US (4) US9845331B2 (OSRAM)
EP (2) EP3313838B1 (OSRAM)
JP (1) JP6997627B2 (OSRAM)
KR (1) KR102663113B1 (OSRAM)
CN (1) CN107873028B (OSRAM)
AR (1) AR105179A1 (OSRAM)
AU (1) AU2016286200B2 (OSRAM)
BR (1) BR122019013677B1 (OSRAM)
CA (1) CA2989499C (OSRAM)
CL (1) CL2017003306A1 (OSRAM)
CO (1) CO2017013713A2 (OSRAM)
CR (2) CR20210297A (OSRAM)
CY (2) CY1122111T1 (OSRAM)
DK (2) DK3313838T3 (OSRAM)
DO (2) DOP2017000295A (OSRAM)
EA (1) EA035383B1 (OSRAM)
ES (2) ES2728356T3 (OSRAM)
HR (2) HRP20190748T1 (OSRAM)
HU (2) HUE043440T2 (OSRAM)
IL (1) IL256393B (OSRAM)
LT (2) LT3313838T (OSRAM)
ME (1) ME03404B (OSRAM)
MX (1) MX371034B (OSRAM)
MY (1) MY201673A (OSRAM)
NI (1) NI201700174A (OSRAM)
PE (1) PE20180530A1 (OSRAM)
PH (1) PH12017502334B1 (OSRAM)
PL (2) PL3313838T3 (OSRAM)
PT (2) PT3539961T (OSRAM)
RS (2) RS62781B1 (OSRAM)
SI (2) SI3313838T1 (OSRAM)
SM (2) SMT201900298T1 (OSRAM)
SV (1) SV2017005598A (OSRAM)
TN (1) TN2017000486A1 (OSRAM)
TR (1) TR201909286T4 (OSRAM)
TW (1) TWI723028B (OSRAM)
WO (1) WO2017001354A1 (OSRAM)
ZA (1) ZA201800563B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200289506A1 (en) 2017-09-25 2020-09-17 Astrazeneca Ab Combination of a btk inhibitor and an inhibitor or cdk9 to treat cancer
WO2019074748A1 (en) * 2017-10-09 2019-04-18 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED PHENYL-OXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
TW202344250A (zh) 2018-11-14 2023-11-16 瑞典商阿斯特捷利康公司 治療癌症之方法
CN114008046B (zh) * 2019-06-27 2023-08-18 南京明德新药研发有限公司 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
AU2020345950A1 (en) * 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
WO2021115335A1 (zh) * 2019-12-09 2021-06-17 石药集团中奇制药技术（石家庄）有限公司 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
WO2021227906A1 (zh) * 2020-05-12 2021-11-18 苏州阿尔脉生物科技有限公司 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
JP7406008B2 (ja) * 2020-05-12 2023-12-26 蘇州阿尓脈生物科技有限公司 Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
TW202216207A (zh) * 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及cdk9抑制劑之組合
US20230271942A1 (en) 2020-08-07 2023-08-31 Pharmablock Sciences (Nanjing), Inc. Cdk9 inhibitor and use thereof
TWI809330B (zh) * 2020-11-20 2023-07-21 大陸商勁方醫藥科技(上海)有限公司 Cdk9抑制劑的多晶型物及其製法和用途
CN115381824B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
CN115381823B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
CN117813289A (zh) * 2021-07-14 2024-04-02 上海海雁医药科技有限公司 吡唑衍生物及其中间体和制备方法
CN115703738B (zh) * 2021-08-16 2024-06-21 中国科学院上海药物研究所 含2-芳杂环取代的脲类化合物、其制备方法和用途
CN118613257A (zh) * 2021-12-23 2024-09-06 鲁汶大学 用于抑制yap/taz-tead的四氢吡唑并嘧啶及相关类似物
AU2023326499A1 (en) 2022-08-17 2025-03-27 Korea Research Institute Of Bioscience And Biotechnology Compounds for inhibiting or decomposing cdk2 and/or cdk9, and medicinal uses thereof
AU2024258350A1 (en) * 2023-04-19 2025-10-30 Alcon Inc. N-substituted c6 cyclyl carboxamide compounds and uses thereof
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133192A1 (ja) 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
JP5693951B2 (ja) 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
US8389521B2 (en) 2007-04-24 2013-03-05 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008129080A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
AU2008309517B2 (en) 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
AU2010291212A1 (en) 2009-09-04 2012-02-23 Novartis Ag Heteroaryl compounds as kinase inhibitors
US20110113038A1 (en) 2009-11-12 2011-05-12 International Business Machines Corporation Search term security
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
CA2789189A1 (en) 2010-03-10 2011-09-15 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
AR081810A1 (es) * 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
KR20140072177A (ko) 2011-10-06 2014-06-12 바이엘 인텔렉쳐 프로퍼티 게엠베하 헤테로사이클릴피리(미)디닐피라졸
BR112015023013A2 (pt) 2013-03-13 2017-07-18 Abbvie Inc inibidores de quinase cdk9
AU2014244183A1 (en) 2013-03-13 2015-08-13 Abbvie Inc. Pyridine CDK9 kinase inhibitors
UY35419A (es) 2013-03-14 2014-10-31 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
AU2014244194A1 (en) 2013-03-14 2015-09-10 Abbvie Inc. Pyrrolopyrimindine CDK9 kinase inhibitors

Also Published As

Publication number Publication date
US20220340592A1 (en) 2022-10-27
SMT201900298T1 (it) 2019-07-11
US9845331B2 (en) 2017-12-19
MY201673A (en) 2024-03-12
PE20180530A1 (es) 2018-03-19
CR20210297A (es) 2021-09-29
PL3313838T3 (pl) 2019-08-30
EA201890094A1 (ru) 2018-07-31
KR102663113B1 (ko) 2024-05-02
SI3539961T1 (sl) 2022-02-28
PL3539961T3 (pl) 2022-02-14
DOP2017000295A (es) 2017-12-31
IL256393A (en) 2018-02-28
US20210171541A1 (en) 2021-06-10
JP6997627B2 (ja) 2022-01-17
DOP2018000207A (es) 2018-10-15
PT3539961T (pt) 2021-12-20
BR112017027394A2 (pt) 2018-11-06
DK3539961T3 (da) 2022-01-03
EP3539961A1 (en) 2019-09-18
AR105179A1 (es) 2017-09-13
MX2017016244A (es) 2018-04-20
PH12017502334B1 (en) 2023-05-26
SV2017005598A (es) 2018-02-23
ZA201800563B (en) 2022-08-31
HRP20190748T1 (hr) 2019-06-14
AU2016286200A1 (en) 2018-02-08
PH12017502334A1 (en) 2018-06-25
HRP20211970T1 (hr) 2022-03-18
CY1125066T1 (el) 2023-03-24
KR20180021830A (ko) 2018-03-05
PT3313838T (pt) 2019-06-24
EP3539961B1 (en) 2021-10-06
HUE043440T2 (hu) 2019-08-28
RS58712B1 (sr) 2019-06-28
CN107873028B (zh) 2021-02-02
AU2016286200B2 (en) 2018-10-04
CN107873028A (zh) 2018-04-03
CA2989499C (en) 2023-10-31
SI3313838T1 (sl) 2019-06-28
DK3313838T3 (da) 2019-06-11
CY1122111T1 (el) 2020-11-25
ES2728356T3 (es) 2019-10-23
ES2902148T3 (es) 2022-03-25
US20180093998A1 (en) 2018-04-05
CO2017013713A2 (es) 2018-03-28
TN2017000486A1 (en) 2019-04-12
BR122019013677B1 (pt) 2024-01-02
LT3313838T (lt) 2019-06-10
TW201718573A (zh) 2017-06-01
EP3313838B1 (en) 2019-04-03
WO2017001354A1 (en) 2017-01-05
LT3539961T (lt) 2021-12-27
NI201700174A (es) 2018-10-19
HUE057343T2 (hu) 2022-05-28
EA035383B1 (ru) 2020-06-04
EP3313838A1 (en) 2018-05-02
IL256393B (en) 2021-12-01
CL2017003306A1 (es) 2018-06-29
RS62781B1 (sr) 2022-01-31
MX371034B (es) 2020-01-13
US11352369B2 (en) 2022-06-07
SMT202200005T1 (it) 2022-03-21
TR201909286T4 (tr) 2019-07-22
US10717746B2 (en) 2020-07-21
CR20170596A (es) 2018-07-04
JP2018522869A (ja) 2018-08-16
CA2989499A1 (en) 2017-01-05
US20160376287A1 (en) 2016-12-29
TWI723028B (zh) 2021-04-01

Similar Documents

Publication Publication Date Title
ME03404B (me) Derivati policikličnih amida kao cdk9 inhibitori
IL268004B (en) History of tyrosine amide as rho-kinase inhibitors
IL275353A (en) Amide-converted indole compounds for use as TLR inhibitors
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA45646A (fr) Derives de benzimidazole comme des modulateurs de ror-gamma
EP3416964A4 (en) Carboxamide derivatives as RSK inhibitors
IL269803A (en) Implications of 6-pyrimidine-isoindole as an ERK1/2 inhibitor
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP3380970A4 (en) NOVEL AZOL DERIVATIVES AS APELIN RECEPTOR AGONISTS
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA49127A (fr) Dérivés d'indole n-substitués
MA49006A (fr) Inhibiteurs d'ip6k
IL269695A (en) Compounds useful as inhibitors of alcat 1
EP3541374A4 (en) AS INHIBITORS OF DIACYLGLYCERID-O-ACYLTRANSFERASE 2 USEFUL INDAZOL DERIVATIVES
EP3532479A4 (en) AMID COMPOUNDS AS A KINASE INHIBITOR
DK3562921T3 (da) Smøremiddelsammensætning indbefattende n-alkyleret dianilin
EP2976338A4 (en) N- (2-CYANO-HETEROCYCLYL) PYRAZOLPYRIDONE AS JANUSKINASEINHIBITORS
MA51285A (fr) Dérivés d'azaindole comme inhibiteurs de rho-kinase
EP3486231A4 (en) PYRROLIDINE DERIVATIVE AS PPAR AGONIST
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
EP3312172A4 (en) aminopyrazole